Det er jo klart dette er noe Pho skulle gjort for lenge siden, av eget initiativ, men den organisasjonen har jo bevist at de ikke klarer selv den enkleste ting uten kyndig veiledning.
Jeg er villig til Ä sette en Bugg (hvis de fortsatt er Ä fÄ tak i) pÄ at Asieris skrapte pÄ dÞrene for Ä fÄ en avtale med Pho.
âŠog det at Cysview/Hexvix sannsynligvis har en terapeutisk effekt, noe en har sett indikasjoner pĂ„ i mange Ă„r allerede, er veldig nedtonet.
We are able to report the first upper tract blue light cystoscopy, and with it, diagnose upper tract CIS. Regular white light examination of the upper tract appeared to be normal, while blue light examination revealed red, porphyrin fluorescence of the distal ureteral wall suspicious for CIS. Biopsies of this area under blue light led to diagnosis of upper tract disease that otherwise would have been omitted. Patient was offered, and agreed to undergo, upper tract dual laser ablation and pelvicalyceal BCG. His three month follow up surveillance ureteroscopy is pending.
Photodynamic surgery using blue light with Cysview uniquely added to the diagnostic and therapeutic treatment of insidious upper tract urothelial carcinoma in a patient with a wide, patulous ureteral orifice. To our knowledge, this is the first instance of using blue light to evaluate the upper tract for UTUC. The patientâs pathology was confirmed by biopsy to be CIS, and evaluation with white light alone likely would have understaged the patient without the assistance of alternate wavelength diagnostics utilizing HAL.
SÄ blir jo spÞrsmÄlet: hvordan skal PHO tjene penger pÄ upper trackt CIS?
10 Ă„r med fase 1, 2, 3 osv?
Eller se det som endnu en fugl pĂ„ taget imens konen er ved at klare gĂžre aftensmaden af de fugle som allerede er skudtđ
Er der nogen med LĂŠgevidenskabeligt baggrund der kan KORT forklare hvad dette betyder og hvad der er fantastisk her 
Bare sÄdan almindelige dÞdelige forstÄr 
Eller er jeg den eneste der ikke helt er med 
SpĂŠndende tider 
Dansken
Uten Ă„ kommentere âLĂŠgevidenskabeligt baggrundâ betyr ikke dette noe annet enn at ikke bare urinblĂŠren, men ogsĂ„ urinlederen fra blĂŠre til nyre, kan fĂ„ kreft tilsvarende blĂŠren. Dermed kan Cysview med sine fordeler ogsĂ„ benyttes der til Ă„ diagnostisere omfang av pĂ„vist kreft.
De skriver at det dermed kan pÄvises kreft som ellers ikke ville blitt oppdaget (med hvitt lys).
Det har ikke vÊrt gjort et slikt studium tidligere. 5-10% av de med blÊrekreft har ogsÄ kreft i urinlederen.
Asieris er fremoverlente, sÄ jeg blir ikke overrasket om de kunne tenke seg Ä teste dette. Pho mÄ for guds skyld ikke ta i dette, la proffene hÄndtere en evt utvikling. Det var vel Hestdal som kunne F&U-biten Ä han er borte for lenge siden.
Viser hvor viktig teknologien er. Enkelt og greit! Smart Ä videreutvikle nÄr det nÄ ser ut til at PHO og partneren ser ut til Ä fÄ to produkter til markedet 1702 og 1706. NDA sÞknad og avventer markedstilgang basert pÄ ventet tilbakemelding fra regulatoriske myndigheter. Greit Ä ha en bred og solid portefÞlje!
Vil neppe tro at det trengs en egen godkjennelse for urinveien. Det benyttes samme utstyr, samme metodikk og samme diagnostikk. Det kan rett og slett gi Photocure et âgratisâ tilleggsomrĂ„de for behandling med dertil Ăžkt omsetning til fĂžlge.
Enig 
Tak for en god forklaring 
Dansken
Mon tro hva neste trekk fra DS og styret blir ?
Spennende tider 
Terapautisk virkning er kanskje et kommende omrÄde?
Det nevnes altfor ofte til at en ikke mÄ anta at dette omrÄdet er av en vesentlig stÞrrelse , ja , hvem vet hvor mye PHO har av nye produkter under utvikling.
Photocure fĂ„r nytt patent i USA â Ă„pner muligheter for ny indikasjon
Blir spennende Ä se pÄ mandag om vi fortsatt holder momentet oppe.
Steady Progress in Commercialization, APL-1702 Submits NDA in China
www.eastmoney.com
August 30, 2024
Southwest Securities
Du Xiangyang, Tang Taimeng
nvestment Highlights
Event: The company released its 2024 semi-annual report, achieving operating revenue of 80.49 million RMB and R&D investment of 150 million RMB during the reporting period. The growth in operating revenue is attributed to the steady progress in the commercialization of Pazopanib tablets (brand name: Dipate) and Neratinib Maleate tablets (brand name: Ouyoubi?) during the reporting period.
APL-1702 Submits NDA in China, Actively Seeking Overseas Collaboration Opportunities.
APL-1702 (Xivita) is a photodynamic therapy product that combines both drug and device components. The international multicenter Phase III clinical trial of APL-1702 was successful, with the response rate in the APL-1702 treatment group increasing by 89.4% compared to the placebo control group (41.1% vs. 21.7%, p=0.0001), demonstrating significant efficacy. The NDA submission for APL-1702 was accepted by the National Medical Products Administration (NMPA) in May 2024. The company plans to submit a pre-submission communication application to the European Medicines Agency (EMA) in the fourth quarter of 2024, and aims to engage with the U.S. FDA on the design of the registration clinical trial protocol for the North American market, with the goal of submitting an application to conduct a Phase III registration clinical study in North America in due course.
APL-1202 in Combination with Tislelizumab for Neoadjuvant Treatment of MIBC Expected to Read Out Phase II Data in September.
APL-1202 is a first-in-class oral, reversible MetAP2 inhibitor that has entered Phase III clinical development. The interim analysis of the Phase II clinical trial for the combination of APL-1202 and Tislelizumab for neoadjuvant treatment of muscle-invasive bladder cancer (MIBC) showed positive results, with a significant increase in the pCR rate compared to the Tislelizumab monotherapy group. The data from the Phase II trial for the APL-1202 and Tislelizumab combination is expected to be read out in September 2024.
Marketing Team and System Maturing, Strong Sales Growth.
The company has introduced Pazopanib tablets and Neratinib Maleate tablets, both of which are oral medications that are convenient to take and have been included in the medical insurance reimbursement list, focusing on urogenital disorders and breast cancer. The company continues to refine its marketing plan for APL-1706, actively exploring outpatient examination scenarios and third-party strategic partnerships, in addition to the existing surgical treatment scenarios, to further expand the commercial opportunities for APL-1706 and benefit more patients. The company is gradually planning and implementing post-marketing access, pricing, expert support, clinical cooperation, and distributor system development.
Earnings Forecast:
With the commercialization of APL-1702, APL-1706, and generic drugs, we expect the companyâs revenue for 2024-2026 to be 200 million, 370 million, and 620 million RMB, respectively.
Potensielt inntekter pÄ 500 millioner til 1 milliard kr om 1-2 Är.
Konservative tall vil jeg pÄstÄ.
Jeg har ikke sagt et ord. 
Hva tenker du?
Ser da lovende ut i boken. 33k pÄ kjÞp pÄ 54.1 kr. Lite til salgs.
Stadig vekk denne jodlingen her ja
Edit:
For lite volum pÄ fredag til Ä drive noen videre oppgang, sÄ helt naturlig at den flater ut her
~52 - ~57 ny tradingrange?
Hvorfor sier du det? Det ble omsatt for ~14 millioner kroner / 260k aksjer (vs. 200k pÄ torsdag). At det ikke omsettes masse hittil i dag er en annen sak.
Alt avhenger uansett om man har en nettokjĂžper av volum (eller ikke).
